{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:35:50Z","timestamp":1778056550561,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T00:00:00Z","timestamp":1400716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00120-014-3505-5","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T12:35:37Z","timestamp":1400589337000},"page":"893-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rivaroxaban, Dabigatran und Apixaban","Rivaroxaban, dabigatran and apixaban"],"prefix":"10.1007","volume":"53","author":[{"given":"A.","family":"John","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,22]]},"reference":[{"key":"3505_CR1","doi-asserted-by":"crossref","unstructured":"Witzenbichler PDB (2011) Antikoagulation bei chronischen Herzerkrankungen. Internist (Berl) 52:1301\u20131309","DOI":"10.1007\/s00108-011-2838-z"},{"key":"3505_CR2","first-page":"382","volume":"86","author":"Hua","year":"2010","unstructured":"Hua TD, Vormfelde SV, Abed MA et al (2010) Orale Antikoagulation in der Hausarztpraxis. Z Allg Med 86:382\u2013389","journal-title":"Z Allg Med"},{"key":"3505_CR3","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"European","year":"2010","unstructured":"European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369\u20132429","journal-title":"Eur Heart J"},{"key":"3505_CR4","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eur416","volume":"14","author":"Camm","year":"2012","unstructured":"Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation \u2013 developed with the special contribution of the European Heart Rhythm Association. Europace 14:1385\u20131413","journal-title":"Europace"},{"key":"3505_CR5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00120-013-3263-9","volume":"52","author":"Fischer","year":"2013","unstructured":"Fischer C, L\u00fcmmen G (2013) ASS und Clopidogrel bei urologischen Operationen. Urologe 52:1597\u20131605","journal-title":"Urologe"},{"key":"3505_CR6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"3505_CR7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"3505_CR8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"3505_CR9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archinternmed.2012.4026","volume":"172","author":"Kom\u00f3csi","year":"2012","unstructured":"Kom\u00f3csi A, Vorobcsuk A, Kehl D, Aradi D (2012) Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 172:1537\u20131545","journal-title":"Arch Intern Med"},{"key":"3505_CR10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00392-013-0560-7","volume":"102","author":"Steiner","year":"2013","unstructured":"Steiner T, B\u00f6hm M, Dichgans M et al (2013) Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 102:399\u2013412","journal-title":"Clin Res Cardiol"},{"key":"3505_CR11","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/jth.12164","volume":"11","author":"Poller","year":"2013","unstructured":"Poller L, Jespersen J, Ibrahim S, Pattison A (2013) Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal. J Thromb Haemost 11:1203\u20131205","journal-title":"J Thromb Haemost"},{"key":"3505_CR12","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft (2012) Leitfaden der Akd\u00c4 zum Einsatz der neuen Antikoagulantien Dabigatran (Pradaxa\u00ae) und Rivaroxaban (Xarelto\u00ae) bei nicht valvul\u00e4rem Vorhofflimmern, Version 1.0. http:\/\/www.akdae.de\/Arzneimitteltherapie\/TE\/LF\/PDF\/OAKVHF.pdf"},{"key":"3505_CR13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1160\/TH11-06-0391","volume":"107","author":"Samama","year":"2012","unstructured":"Samama MM, Contant G, Spiro TE et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379\u2013387","journal-title":"Thromb Haemost"},{"key":"3505_CR14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","volume":"172","author":"Uchino","year":"2012","unstructured":"Uchino K, Hernandez AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:397\u2013402","journal-title":"Arch Intern Med"},{"key":"3505_CR15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11739-013-0963-5","volume":"8","author":"Liew","year":"2013","unstructured":"Liew A, Douketis J (2013) Perioperative management of patients who are receiving a novel oral anticoagulant. Intern Emerg Med 8:477\u2013484","journal-title":"Intern Emerg Med"},{"key":"3505_CR16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/21681805.2013.817482","volume":"48","author":"S\u00e4ily","year":"2014","unstructured":"S\u00e4ily VM, P\u00e9tas A, Joutsi-Korhonen L et al (2014) Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation. Scand J Urol 48:153\u2013159","journal-title":"Scand J Urol"},{"key":"3505_CR17","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.purol.2013.04.011","volume":"23","author":"Olivier","year":"2013","unstructured":"Olivier J, Yakoubi R, Gras S et al (2013) Critical haematuria after prostate biopsies with RIVAROXABAN. Case report. Prog Urol 23:1012\u20131014","journal-title":"Prog Urol"},{"key":"3505_CR18","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood-2012-06-415943","volume":"120","author":"Spyropoulos","year":"2012","unstructured":"Spyropoulos AC, Douketis JD (2012) How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120:2954\u20132962","journal-title":"Blood"},{"key":"3505_CR19","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMra1206531","volume":"368","author":"Baron","year":"2013","unstructured":"Baron TH, Kamath PS, McBane RD (2013) Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 368:2113\u20132124","journal-title":"N Engl J Med"},{"key":"3505_CR20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-152-9-201005040-00008","volume":"152","author":"Carrier","year":"2010","unstructured":"Carrier M, Le Gal G, Wells PS, Rodger MA (2010) Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 152:578\u2013589","journal-title":"Ann Intern Med"},{"key":"3505_CR21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/11587290-000000000-00000","volume":"34","author":"Schulman","year":"2011","unstructured":"Schulman S, Majeed A (2011) A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. Drug Saf 34:449\u2013463","journal-title":"Drug Saf"},{"key":"3505_CR22","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.2174\/138161210793563338","volume":"16","author":"Douketis","year":"2010","unstructured":"Douketis JD (2010) Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des 16:3436\u20133441","journal-title":"Curr Pharm Des"},{"key":"3505_CR23","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","volume":"141","author":"Douketis","year":"2012","unstructured":"Douketis JD et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(Suppl 2):e326S","journal-title":"Chest"},{"key":"3505_CR24","doi-asserted-by":"crossref","unstructured":"Beyer-Westendorf J, Gelbricht V, F\u00f6rster K et al (2014) Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J [Epub ahead of print]","DOI":"10.1093\/eurheartj\/eht557"},{"key":"3505_CR25","first-page":"338","volume":"30","author":"Epple","year":"2012","unstructured":"Epple C, Steiner T (2012) Therapie von Blutungskomplikationen bei Antikoagulanzientherapie. Arzneimitteltherapie 30:338\u2013348","journal-title":"Arzneimitteltherapie"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-014-3505-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-014-3505-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-014-3505-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:04:29Z","timestamp":1558609469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-014-3505-5"}},"subtitle":["Neue Antikoagulanzien in der operativen Urologie","New anticoagulants in operative urology"],"short-title":[],"issued":{"date-parts":[[2014,5,22]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["3505"],"URL":"https:\/\/doi.org\/10.1007\/s00120-014-3505-5","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,22]]}}}